Goldenberg G J, Brandes L J
Cancer Res. 1976 Feb;36(2 pt 2):720-3.
Epstein-Barr virus, the apparent cause of infectious mononucleosis, may also be an etiological agent in nasopharyngeal carcinoma and Burkitt's lymphoma. Lymphocytes from normal individuals with anti-Epstein-Barr virus antibody activity may be sensitized to Epstein-Barr virus and contain transfer factor with the potential to program and/or recruit other lymphocytes to react against the virus and/or viral antigens. A patient with nasopharyngeal carcinoma refractory to conventional therapy was treated with transfer factor obtained from normal, young adults with previous history of infectious mononucleosis. Following immunotherapy, apparent slowing of tumor growth was observed, which was associated with intense lymphocytic infiltration of the tumor and reconstitution of delayed cutaneous hypersensitivity reactions to microbial recall antigens. A double-blind randomized clinical trial has been initiated to determine whether transfer factor immunotherapy is a useful adjunct to radiotherapy in the primary treatment of patients with nasopharyngeal carcinoma. If successful, a similar trial might be considered for African patients with Burkitt's lymphoma.
爱泼斯坦 - 巴尔病毒是传染性单核细胞增多症的明显病因，也可能是鼻咽癌和伯基特淋巴瘤的病原体。具有抗爱泼斯坦 - 巴尔病毒抗体活性的正常个体的淋巴细胞可能对该病毒敏感，并含有转移因子，这种转移因子有可能编程和/或募集其他淋巴细胞来对抗该病毒和/或病毒抗原。一名对传统治疗难治的鼻咽癌患者接受了从既往有传染性单核细胞增多症病史的正常年轻成年人中获取的转移因子治疗。免疫治疗后，观察到肿瘤生长明显减缓，这与肿瘤中强烈的淋巴细胞浸润以及对微生物回忆抗原的迟发性皮肤过敏反应的重建有关。一项双盲随机临床试验已经启动，以确定转移因子免疫治疗是否是鼻咽癌患者初始治疗中放疗的有用辅助手段。如果成功，对于患有伯基特淋巴瘤的非洲患者可能会考虑进行类似试验。
